Skip to main content

Susan Halabi CV

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2717, Durham, NC 27710
2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
CV

Overview


Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Current Appointments & Affiliations


James B. Duke Distinguished Professor of Biostatistics & Bioinformatics · 2023 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics · 2012 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Chief, Division of Biostatistics · 2019 - Present Biostatistics & Bioinformatics, Basic Science Departments
Member of the Duke Cancer Institute · 1996 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published February 12, 2025
New Blood Test for Advanced Prostate Cancer Patients
Published May 4, 2023
Duke Awards 44 Distinguished Professorships
Published June 4, 2018
Survival Benefit for African-Americans with Advanced Prostate Cancer

View All News

Recent Publications


Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

Journal Article JCO Precis Oncol · July 2025 PURPOSE: In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought ... Full text Link to item Cite

How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know.

Journal Article Eur Urol · July 1, 2025 Subgroup analyses must be approached with caution. Only prespecified, well-powered analyses with formal interaction testing and validation can support strong claims; exploratory findings require confirmation. Integration of statistical rigor with clinical ... Full text Link to item Cite

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.

Journal Article Prostate Cancer Prostatic Dis · June 2025 BACKGROUND: CALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in over ... Full text Link to item Cite
View All Publications

Recent Grants


Research Triangle Center of Excellence in Regulatory Science and Innovation

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028

DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era

ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026

View All Grants

Education, Training & Certifications


University of Texas Health Sciences Center, Houston · 1994 Ph.D.